The global tuberculosis treatment market reached a value of about USD 1.74 billion in 2023. The market is expected to grow at a CAGR of 7.57% during the forecast period of 2024-2032 to attain a value of USD 3.37 billion by 2032. The growth of the market is driven by the rising favourable government policies to increase demand for tuberculosis (TB) diagnostics.
Tuberculosis (TB) is an infectious disease that primarily affects the lungs. Tuberculosis bacteria spread from person to person via tiny droplets released into the air by coughs and sneezes, it can also attack other organs, such as the kidneys, spine, and brain. Not everyone who is infected with tuberculosis bacteria (germs) becomes ill. There are two kinds of tuberculosis:
The prevalence of tuberculosis is rapidly rising and is likely to continue rising in the coming years as well, driven by the rising number of smokers. Majority of people who have TB germs in their bodies do not develop TB disease, instead, they have latent tuberculosis infection. Tuberculosis can spread when a person with active TB disease sneezes, coughs, sings, talks, or even laughs, anything that involves releasing germs into the air. While latent TB does not get transmitted, active pulmonary infection is highly contagious.
Inactive tuberculosis does not cause symptoms; however, they can be diagnosed with a positive skin reaction test or blood test. Active TB patients may exhibit any of the following symptoms:
There are two types of tuberculosis screening tests, namely Mantoux Tuberculin Skin Test (TST) and Interferon-Gamma Release Assay (blood test) (IGRA).
A healthcare provider will inject a small amount of purified protein derivative (PPD) under the skin of the forearm for the TST.
Additional tests to determine whether an infection is active or whether the lungs are infected include sputum and lung fluid testing, X-ray of the chest, and/or CT scans (computed tomography).
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
According to the market research report, the market can be categorised into the following segments:
Market Breakup by Disease Type
Market Breakup by Therapy Type
Market Breakup by Route of Administration
Market Breakup by Dosage Form
Market Breakup by Distribution Channel
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Region
More than 1.7 billion people (roughly 22% of the world's population) are estimated to be infected with tuberculosis. The global incidence of tuberculosis peaked around 2003 and appears to be slowly declining. According to the World Health Organization (WHO), 9.9 million people became ill with tuberculosis (TB) in 2020, with 1.5 million deaths.
As per the records, in 2021, there was 7,860 tuberculosis cases reported in the United States. The incidence rate in the United States has reached close to 2.4 cases per 100,000 people.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Antibiotics are typically used to treat tuberculosis (TB) in the initial treatment, which goes on for several months. The standard treatment is 6 months of antibiotics (isoniazid and rifampicin). For the first 2 months of the 6-month treatment period, 2 additional antibiotics (pyrazinamide and ethambutol) are administered. Extrapulmonary tuberculosis (TB that occurs outside the lungs) can be treated with the same antibiotic combination as pulmonary tuberculosis.
If tuberculosis is in areas such as the brain or the sac surrounding the heart (pericardium), the patient may be given a corticosteroid such as prednisolone, alongside the antibiotics for several weeks. This will aid in the reduction of swelling in the affected areas.
If latent tuberculosis is thought to be drug-resistant, it is not always treated. If this is the case, the patient may be monitored on a regular basis to ensure that the infection does not become active. For latent tuberculosis patients, the most common prescription includes Rifampicin and isoniazid in combination for 3 months, and Isoniazid alone for 6 months.
The increased public-private partnership, favourable government policies to boost the demand for tuberculosis (TB) diagnostics, and the rising incidence of tuberculosis in high-burden countries are the factors driving the global tuberculosis treatment market.
In the forecast year, the limitations of existing tuberculosis diagnostics will impede the market growth.
The report gives an in-depth analysis of the key players involved in the global tuberculosis treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Disease Type||
|Breakup by Therapy Type||
|Breakup by Route of Administration||
|Breakup by Dosage Form||
|Breakup by Distribution Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Tuberculosis Overview
3.1 Guidelines and Stages
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Tuberculosis Treatment Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Tuberculosis Epidemiology (2016-2031)
5.3 Europe Tuberculosis Epidemiology (2016-2031)
5.4 Asia-Pacific Tuberculosis Epidemiology (2016-2031)
5.5 Latin America Tuberculosis Epidemiology (2016-2031)
5.6 Middle East & Africa Tuberculosis Epidemiology (2016-2031)
6 Global Tuberculosis Treatment Market Overview
6.1 Global Tuberculosis Treatment Market Historical Value (2017-2023)
6.2 Global Tuberculosis Treatment Market Forecast Value (2024-2032)
7 Global Tuberculosis Treatment Market Landscape
7.1 Tuberculosis Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Tuberculosis Treatment: Product Landscape
7.2.1 Analysis by Product
7.2.2 Analysis by End User
8 Tuberculosis Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Tuberculosis Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Tuberculosis Treatment Market Segmentation
11.1 Global Tuberculosis Treatment Market by Disease Type
11.1.1 Market Overview
11.1.2 Active Tuberculosis
11.1.3 Latent Tuberculosis
11.2 Global Tuberculosis Treatment Market by Therapy Type
11.2.1 Market Overview
11.2.2 First Line Therapy
11.2.3 Second Line Therapy
11.3 Global Tuberculosis Treatment Market by Route of Administration
11.3.1 Market Overview
11.4 Global Tuberculosis Treatment Market by Dosage Form
11.4.1 Market Overview
11.5 Global Tuberculosis Treatment Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacy
11.5.3 Retail Pharmacy
11.5.4 Online Pharmacy
11.6 Global Tuberculosis Treatment Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Tuberculosis Treatment Market
12.1 Market Share by Country
12.2 United States of America
13 Europe Tuberculosis Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
14 Asia Pacific Tuberculosis Treatment Market
14.1 Market Share by Country
15 Latin America Tuberculosis Treatment Market
15.1 Market Share by Country
16 Middle East and Africa Tuberculosis Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.5 South Africa
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Johnson and Johnson Services, Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.2 Lupin Ltd
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.3 Novartis AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.4 Macleods Pharmaceuticals Ltd.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.5 Otsuka Pharmaceutical Co., Ltd
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.6 Pfizer Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.7 AstraZeneca Plc
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.8 Cipla Ltd
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.9 Alkem Laboratories Ltd
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.10 Eli Lilly And Company
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.11 F. Hoffmann-La Roche Ltd.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.12 Viatris Inc. (Mylan N.V.)
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.13 Teva Pharmaceutical Industries, Ltd.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
24 Tuberculosis Treatment - Distribution Model (Additional Insight)
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The global tuberculosis treatment market reached a value of about USD 1.74 billion in 2023, rising favourable government policies to increase demand for tuberculosis (TB) diagnostics.
The market is expected to grow at a CAGR of 7.57% during the forecast period of 2024-2032 to attain a value of USD 3.37 billion by 2032.
The increased public-private partnership, favourable government policies to boost the demand for tuberculosis (TB) diagnostics, and the rising incidence of tuberculosis in high-burden countries are the key factors driving the global tuberculosis treatment market growth.
Tuberculosis can be categorized into two types- active tuberculosis and latent tuberculosis.
The treatment types can be divided into first line therapy and second line therapy.
The route of administration includes oral and parenteral, among others.
The dosage types can be categorized into tablets, capsules, and injections, among others.
The distribution channels used in the market include hospital pharmacy, retail pharmacy, and online pharmacy.
The key players in the market include Johnson and Johnson Services, Inc., Lupin Ltd, Novartis AG, Macleods Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., AstraZeneca Plc, Cipla Ltd, Alkem Laboratories Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Viatris Inc. (Mylan N.V.), and Teva Pharmaceutical Industries, Ltd., among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.